---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-199246"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2022-07-21T23:59:59+00:00"
generated_at: "2026-06-24T10:03:01.592472+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Silverback Therapeutics to merge with ARS Pharmaceuticals; focus on needle-free epinephrine nasal spray neffy

## Summary
- Silverback equity holders expected to own ~37%, ARS holders ~63% on fully-diluted basis.
- Combined company expected to have ~$265M cash at close; merger expected Q4 2022; ticker to change to 'SPRY'.
- Silverback to reduce workforce by ~73% by Sept 2, 2022; severance charges ~$13M cash + $2M non-cash.
- ARS preparing NDA submission for neffy in Q3 2022; potential US launch in 2023.
- Combined company CEO will be Rich Lowenthal (ARS); board of 10 members (7 from ARS, 3 from Silverback).

## SEC filing metadata
- accession: 0001193125-22-199246
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2022-07-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312522199246/0001193125-22-199246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312522199246/d379554d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-199246
- JSON: https://secwatch.observer/filing/0001193125-22-199246.json
- Plain text: https://secwatch.observer/filing/0001193125-22-199246.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.